Kiniksa Pharmaceuticals International (KNSA) Prepaid Assets (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Prepaid Assets came in at $48.3 million in Q2 2026, up 48.85% on a YoY basis from $32.4 million in Q2 2025, and up 62.5% quarter-over-quarter from $29.7 million in Q1 2026.
Analysis
Kiniksa Pharmaceuticals International (KNSA) Prepaid Assets (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Prepaid Assets for 10 consecutive years, with $48.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets rose 48.85% year-over-year to $48.3 million; the trailing twelve-month figure through Jun 2026 stood at $48.3 million (up 48.85% YoY), and the FY2025 full-year result was $42.6 million, up 112.18% from the prior year.
- Prepaid Assets improved to $48.3 million in Q2 2026 per KNSA's latest filing, from $29.7 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $48.3 million in Q2 2026 and bottomed at $10.5 million in Q1 2022.
- Historically, Prepaid Assets has averaged $23.5 million across 5 years, with a median of $22.8 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets dropped 11.18% in 2023, then jumped 116.67% in 2024.
- Over 5 years, Prepaid Assets stood at $10.5 million in 2022, then jumped by 66.44% to $17.5 million in 2023, then increased by 14.52% to $20.1 million in 2024, then soared by 112.18% to $42.6 million in 2025, then climbed by 13.31% to $48.3 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $48.3 million, $29.7 million, and $42.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.12 Bn | 5.60 Bn | 220.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.29 Mn |
| Mar 31, 2026 | 29.71 Mn |
| Dec 31, 2025 | 42.61 Mn |
| Sep 30, 2025 | 30.29 Mn |
| Jun 30, 2025 | 32.44 Mn |
| Mar 31, 2025 | 25.43 Mn |
| Dec 31, 2024 | 20.08 Mn |
| Sep 30, 2024 | 33.95 Mn |
| Jun 30, 2024 | 26.95 Mn |
| Mar 31, 2024 | 13.77 Mn |
| Dec 31, 2023 | 17.54 Mn |
| Sep 30, 2023 | 26.40 Mn |
| Jun 30, 2023 | 12.44 Mn |
| Mar 31, 2023 | 13.16 Mn |
| Dec 31, 2022 | 10.54 Mn |
| Sep 30, 2022 | 15.31 Mn |
| Jun 30, 2022 | 14.01 Mn |
| Mar 31, 2022 | 10.52 Mn |
| Dec 31, 2021 | 6.59 Mn |
| Sep 30, 2021 | 8.50 Mn |